Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07467993 · ClinicalTrials.gov registry record · Phase 2

Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia

A Phase 2 study of Schizophrenia, sponsored by Novartis Pharmaceuticals.

Recruiting
Registry status
Phase 2
Development phase
142
Enrollment target
2
Study locations

NCT07467993 is a Phase 2 study of Schizophrenia that is actively recruiting participants, run by Novartis Pharmaceuticals. The registered enrollment target is 142 participants, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (35% lower). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07467993, a Phase 2 study of Schizophrenia, is actively recruiting participants, sponsored by Novartis Pharmaceuticals.

RECRUITING
Registry status
Phase 2
Development phase
142 participants
Enrollment target
2
Study locations

Study Summary

The purpose of this study is to assess the efficacy, safety, and tolerability of GXV813 in the treatment of an acute episode of schizophrenia

Conditions Studied

Schizophrenia

Interventions

  • DRUG Placebo
  • DRUG GXV813

Study Locations (2)

Illinois

  • Uptown Research Institute LLC - Chicago

Missouri

  • Arch Clinical Trials LLC - St Louis

Trial Details

FieldValue
Enrollment Target 142 participants
Start Date 2026-03-16
Est. Completion 2027-04-27
Phase Phase 2

Sponsor

Novartis Pharmaceuticals

1,375 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07467993

The ClinicalTrials.gov registry entry for NCT07467993 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 142 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (35% lower). The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Schizophrenia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT07467993 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Illinois, Missouri.

Frequently Asked Questions

What is clinical trial NCT07467993 about?

NCT07467993 is a clinical study titled "Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia". The purpose of this study is to assess the efficacy, safety, and tolerability of GXV813 in the treatment of an acute episode of schizophrenia

What is the current status of trial NCT07467993?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 142 participants. The study started on 2026-03-16. Estimated completion is 2027-04-27.

What conditions does trial NCT07467993 study?

This clinical trial studies the following conditions: Schizophrenia.

What interventions are being tested in trial NCT07467993?

The interventions under investigation include: Placebo (DRUG), GXV813 (DRUG).

Who is sponsoring clinical trial NCT07467993?

This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07467993 being conducted?

This trial has 2 study locations across Illinois, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Schizophrenia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Schizophrenia

All registered trials for this condition

Illinois

All trials with a study site in Illinois

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.